ABSTRACT
A patient with idiopathic myelofibrosis is reported who developed a drug fever after treatment with hydroxyurea, a generally effective and well-tolerated drug in chronic myeloproliferative syndromes. Typically, this form of fever develops after a few weeks of exposure to the drug and disappears with discontinuation of the drug. Possible interactions with prostaglandin or leukotriene metabolism may play a role.
Subject(s)
Fever/chemically induced , Hydroxyurea/adverse effects , Primary Myelofibrosis/drug therapy , Aged , Humans , MaleSubject(s)
Hemangiopericytoma/pathology , Lipoma/pathology , Neoplasm Recurrence, Local/pathology , Neoplasms, Multiple Primary/pathology , Soft Tissue Neoplasms/pathology , Spinal Neoplasms/pathology , Thoracic Vertebrae/pathology , Actins/analysis , Adult , Humans , Immunoenzyme Techniques , Male , Middle Aged , Spinal Cord Compression/pathologyABSTRACT
Non-Hodgkin lymphoma was diagnosed initially in a curettage specimen of a puerperal uterus 3 weeks after normal delivery of a healthy infant. The disease, which probably existed during the last trimester of pregnancy, was classified as clinical stage IVb. Combination chemotherapy resulted in immediate improvement and complete remission after several months. Histopathologic examination of the uterus 10 months after starting therapy demonstrated complete disappearance of the malignant lymphoma.
Subject(s)
Lymphoma, Non-Hodgkin , Pregnancy Complications, Neoplastic , Puerperal Disorders , Uterine Neoplasms , Adult , Female , Humans , Infant, Newborn , Lymphoma, Non-Hodgkin/diagnosis , Lymphoma, Non-Hodgkin/pathology , Lymphoma, Non-Hodgkin/therapy , Pregnancy , Pregnancy Complications, Neoplastic/diagnosis , Puerperal Disorders/diagnosis , Puerperal Disorders/pathology , Puerperal Disorders/therapy , Uterine Neoplasms/diagnosis , Uterine Neoplasms/pathology , Uterine Neoplasms/therapyABSTRACT
In this longitudinal study we measured beta-TG, PF4, fibrinolytic activity (extrinsic and euglobulin fraction), fibrinogen, FVIII RAg and FVIII Rcof before and after i.v. DDAVP (FPA was only measured before DDAVP) in 20 patients with diabetes mellitus. These parameters were measured on three occasions: phase I: during disregulation, phase II: after three weeks of strict control, phase III: after nine weeks of good control. Twenty-two healthy volunteers served as normal controls. No significant differences related to metabolic control were found for beta-TG, PF4, FPA and fibrinogen. There was no change after i.v. DDAVP administration. Fibrinolytic activity showed a significant increase after i.v. DDAVP. Baseline values and post-DDAVP increase were not significantly different from our normal controls. FVIII RAg and FVIII Rcof were both significantly elevated in diabetes mellitus. Both increased significantly after DDAVP. The FVIII RAg release (delta FVIII RAg) was significantly less in the diabetics. Fibrinolytic activity, FVIII RAg and FVIII Rcof are independent of the degree of metabolic control in patients with diabetes.
Subject(s)
Arginine Vasopressin/pharmacology , Deamino Arginine Vasopressin/pharmacology , Diabetes Mellitus/blood , Adult , Aged , Antigens/analysis , Blood Coagulation/drug effects , Blood Platelets/drug effects , Blood Platelets/metabolism , Diabetic Angiopathies/etiology , Factor VIII/immunology , Female , Fibrinolysis/drug effects , Humans , Male , Middle AgedABSTRACT
Forty-one adult diabetic patients of either sex who had been controlled by insulin alone for at least one year were randomly allocated in a double-blind, between-patient study, to either sulphinpyrazone (600--800 mg daily) or an identnd at the end of it, no clinically or statistically significant change of the insulin needs of the patients was observed. It is concluded that no clinical interaction occurs between sulphinpyrazone (800 mg/day or 600 mg/day) and insulin when they are administered simultaneously for long periods. In the doses used the tolerability of sulphinpyrazone was very good.
